Please login to the form below
FSG
This page shows the latest FSG news and features for those working in and with pharma, biotech and healthcare.
Retrophin rockets away as rare disease trial hits targets
Now, the company says a phase II trial of sparsentan in focal segmental glomerulosclerosis (FSG), a rare disease characterised by progressive scarring of the kidneys that often leads to kidney failure, ... Leerink analyst Joseph Schwartz has suggested
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Featured jobs
-
Account Director – UK Office
-
Excellent salary and benefits
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
-
Senior Medical Writer
-
Competitive salary plus benefits
- Account Manager – Healthcare advertising
-
Salary TBC
- Client Services Director- Flexible Working
-
Negotiable
-
Events Executive
-
DOE
Subscribe to our email news alerts
- Novartis eyes potential new indication for Cosentyx
- J&J's Tremfya filed for approval in US for psoriatic arthritis
- AbbVie/Allergan's merger faces public opposition
- Envision Pharma Group relocates to support expansion
- Biogen loses another pipeline drug to toxicity concerns
- AZ, Merck’s Lynparza scores market-expanding clinical success
- Report: Customer experience, shaping digital healthcare
- The benefits of uniting in a divergent environment
- Encouraging signs in biomarker R&D
- J&J puts pressure on rivals with new Erleada okay in prostate cancer
- Pharma exhibition stand design with added value
- Bluebird Bio reveals further encouraging data for CALD gene therapy
PMHub
Novasecta
We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...
Latest intelligence
- Report: Customer experience, shaping digital healthcare
- In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
- Encouraging signs in biomarker R&D
- The cancer immunotherapy firms ramping-up biomarker R&D...
- Programmatic methodology and why you should be using it
- What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...
Quick links
Infographics
